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group (9.5 ± 1.9 vs. 10.2 ± 2.2 m/s, p < 0.01) and haemodi-
alysis to haemodiafiltration group (9.4 ± 1.9 vs. 10.1 ± 2.2 
m/s, p < 0.01), but did not change with haemodiafiltration 
(9.9 ± 2.1 vs. 10.1 ± 2.2 m/s).  Conclusions: Aortic PWV, a mea-
sure of vascular stiffness, stabilised with haemodiafiltration. 
Our preliminary findings require further investigation to de-
termine how haemodiafiltration may potentially improve 
vascular stiffness.  © 2014 S. Karger AG, Basel 
 Introduction 
 The prevalence of cardiovascular and cerebrovascular 
diseases is increased for patients with chronic kidney dis-
ease (CKD) stage 5 treated by dialysis (CKD5d)  [1] . Com-
pared to the general population, patients with CKD5d 
have increased rates of sudden cardiac death, heart failure 
and stroke  [2] . Increased aortic stiffness with a corre-
spondingly increased pulse pressure in the central arteries 
has repeatedly been reported as an independent predictor 
of cardio- and cerebrovascular events in both the general 
population  [3] and also those with CKD5d  [4] .
 Haemodiafiltration, which adds convective clearance 
to standard haemodialysis treatments, is becoming more 
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 Abstract 
 Background/Aims: Cerebrovascular diseases such as stroke 
are increased in dialysis patients, and haemodiafiltration has 
been reported to reduce cerebrovascular mortality com-
pared to haemodialysis. We wished to determine whether 
haemodiafiltration improves arterial stiffness.  Methods: We 
audited aortic pulse wave velocity (PWV) measurements 6 
months apart in 3 cohorts of patients: 69 treated with hae-
modialysis, 78 who converted from haemodialysis to hae-
modiafiltration and 142 treated with haemodiafiltration.
 Results: Cohorts were well matched for age (means ± SD: 
haemodialysis 64 ± 15 years vs. haemodialysis to haemodi-
afiltration 64 ± 17 years vs. haemodiafiltration 67 ± 16 years), 
sex (male 65 vs. 59 vs. 63%), diabetes (45 vs. 56.4 vs. 44%) 
and body mass index (26 ± 6 vs. 26 ± 5 vs. 26 ± 5), respec-
tively. Systolic blood pressure did not differ over time (hae-
modialysis 143 ± 25 vs. 146 ± 27 mm Hg, haemodialysis to 
haemodiafiltration 153 ± 26 vs. 154 ± 25 mm Hg, haemodi-
afiltration 149 ± 31 vs. 148 ± 30 mm Hg) or between groups. 
Aortic PWV significantly increased in the haemodialysis 
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widely available  [5] . Although haemodiafiltration does 
not lead to any discernible improvements in blood pres-
sure control in CKD5d patients  [6] , it increases middle-
sized molecular weight solute clearances and improves 
phosphate control compared to standard haemodialysis 
 [7] . More recently, a prospective trial of haemodiafiltra-
tion reported increased all-cause survival and in particu-
lar reduced cerebrovascular deaths compared to standard 
haemodialysis  [8] .
 Pulse wave velocity (PWV), an assessment of aortic 
stiffness, can be reliably measured at the bedside  [9, 10] . 
We hypothesised that although haemodiafiltration does 
not improve blood pressure control, it may improve vas-
cular reactivity with a reduction in vascular stiffness. To 
investigate this hypothesis we audited PWV measure-
ments in CKD5d patients treated with haemodialysis, 
haemodiafiltration and those converted from haemodi-
alysis to haemodiafiltration to determine whether hae-
modiafiltration resulted in any beneficial effect on PWV.
 Patients and Methods 
 In adult CKD5d outpatients attending for their routine mid-
week dialysis treatments, aortic PWV measurements were per-
formed before dialysis and then repeated after 6 months. All dialy-
sis centres were temperature controlled. Aortic-brachial PWV was 
measured by a single observer using the Tensio Clinic Arterio-
graph (TensioMed Kft., Budapest, Hungary) oscillometric meth-
od, which has been validated against direct invasive measurements 
 [9–11] . The distance between jugular notch and symphysis pubis 
was measured with a specially designed measuring device, and, af-
ter patients had rested, measurements were made in the recumbent 
position in the non-fistula arm.
 All patients attending for dialysis were to be included; however, 
PWV measurements were not able to be recorded in patients with 
atrial fibrillation, other cardiac arrhythmias and fistulae in both 
arms, and in patients with no recordable upper arm blood pres-
sure, and we excluded patients with severe aortic stenosis.
 Augmentation indices (AXi) were calculated for the aorta and 
brachial arteries as the difference between the amplitudes of the 
late (backward) systolic wave (P2) and the early (forward) systolic 
wave (P1) over the pulse pressure (PP) multiplied with 100 [AXi = 
(P2 – P1)/PP  ∙ 100], and then adjusted for heart rate. The diastolic 
relaxation area (DRA), a measure of diastolic filling of the left cor-
onary artery, was also adjusted for heart rate.
 The Royal Free Hospital has no hospital-based dialysis facility 
and all CKD5d outpatients dialyse in satellite dialysis centres. Pa-
tient allocation to satellite centres was based on their post code 
(designed to minimise journey time to and from dialysis centres) 
and not on co-morbidity.
 At the time of the blood pressure audit, the Royal Free Hospital 
was introducing haemodiafiltration as the standard of care for 
CKD5d patients. As such, some dialysis centres provided only hae-
modiafiltration, some haemodialysis and some converted from hae-
modialysis to haemodiafiltration during the 6-month audit period.
 All patients were dialysed thrice weekly, targeted to achieve an 
online Kt/V clearance of  ≥ 1.4 (Fresenius 4008/5008: Fresenius, 
Bad Homberg, Germany; Dialog+: B. Braun Medical Inc., Melsun-
gen, Germany), using polysulfone dialysers (Nipro, Osaka, Japan) 
 [12] and ultrapure quality dialysate, and anti-coagulated with 
tinzaparin (Leo Laboratories, Market Harborough, UK)  [13] . On-
line post-dilutional haemodiafiltration was targeted to achieve >16 
litres per convective therapy session  [14] . Dialysate temperature 
was set at 35–35.5  °  C, and dialysate sodium was regularly checked 
by flame photometry (Flame Photometer 943; Instrumentation 
Laboratory, Warrington, UK) with appropriate aqueous standards 
to ensure quality control  [15] . Dialysate bicarbonate was set at 32 
mmol/l with 3 mmol/l of acetate.
 A standard automated laboratory multichannel analyser was 
used for biochemical testing, with albumin measured using the 
bromocresol green method (Roche Integra; Roche Diagnostics, 
Lewes, UK). Subsets of patients had attended for transthoracic 
2-dimensional echocardiograms (Philips IE33; Philips Medical 
Systems, Eindhoven, The Netherlands) or cardiac stress testing us-
ing adenosine triphosphate myocardial perfusion scintigraphy on 
a non-dialysis day  [16] .
 Table 1.  Baseline demographics of the patients on high-flux hae-
modialysis (HD) and online post-dilution haemodiafiltration 
(HDF), and those who converted from HD to HDF
HD HD to HDF  HDF
Patients, n 69 78 142
Age, years 64.2 ± 15.2 64.1 ± 16.5 67.0 ± 19.7
Males, % 65.2 59.0 62.6
Diabetics, % 44.9 56.4 44.4
Weight, kg 72.5 ± 16.6 71.9 ± 17.5 70.5 ± 16.3
Body mass index 26.1 ± 5.8 25.8 ± 5.2 25.7 ± 5.2
Dialysis vintage,
months 24 (7 – 52) 28.5 (14 – 50) 39 (21 – 75)*
Dialysis session, h 3.92 ± 0.36 3.93 ± 0.42 3.99 ± 0.37
Hypertension, % 72.2 66.7 85.9
IHD, % 20.3 32.1 31.7
PVD, % 14.5 14.1 23.9
CVD, % 8.7 12.8 19.7
Current smokers, % 14.5 13.7 3.5
Ex-smokers, % 29.0 27.5 24.6
ACEI/ARB, % 33.3 33.3 31.5
CCB, % 24.6 15.4 22.5
BB, % 42.0 12.8* 19.7*
 Results are expressed as means ± SD or medians (interquartile 
ranges). IHD = Ischaemic heart disease (myocardial infarction,
coronary artery stenting or bypass surgery); PVD = peripheral vas-
cular disease (amputation, angioplasty or claudication); CVD = 
cerebrovascular disease (stroke or transient ischaemic attack); 
ACEI = angiotensin-converting enzyme inhibitors; ARB = angio-
tensin receptor blockers; CCB = calcium channel blockers; BB = 
β-blockers. * p < 0.05 by χ2 or ANOVA with post hoc correction 
vs. HD.
D
ow
nl
oa
de
d 
by
: 
UC
L 
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
14
4.
82
.1
07
.8
9 
- 3
/2
4/
20
15
 3
:2
1:
28
 P
M
 Haemodiafiltration and Pulse Wave 
Velocity 
Nephron Clin Pract 2014;128:185–191
DOI: 10.1159/000368242
187
 This retrospective audit fulfilled the UK Department of Health 
audit guidelines for clinical service development and was approved 
by the Royal Free Hospital Research and Development Office (In-
ternational Clinical Trials Registry No. ISRCTN70556765).
 Statistical Analysis 
 Statistical analysis was by Student’s t test and Wilcoxon rank 
sum test for paired data, and χ 2 test and one-way ANOVA or 
Kruskal-Wallis test with Tukey or Dunn’s post hoc analysis cor-
rection (SPSS, version 20.0; SPSS Inc., Chicago, Ill., USA). Data 
are expressed as means ± SD, medians and interquartile ranges, 
or percentages. Statistical significance was taken at or below the 
5% level.
 Results 
 PWV was measured 6 months apart in 69 CKD5d HD 
patients, 142 patients treated with haemodiafiltration and 
78 patients who had converted from haemodialysis to 
haemodiafiltration during the audit cycle. The groups 
were well matched in terms of demographics and past 
medical history ( table 1 ), although there were fewer self-
reported current smokers in the haemodiafiltration 
group, but similar numbers of ex-smokers. Similar num-
bers of patients were treated with anti-hypertensives, al-
though proportionally more patients in the haemodialy-
sis group were prescribed β-blockers.
 Serum bone mineral biochemistry and lipid profiles 
were similar between the groups at baseline ( table 2 ) and 
follow-up (online suppl. table 1; for all online suppl. ma-
terial, see www.karger.com/doi/10.1159/000368242), and 
similar numbers were prescribed lipid-lowering drugs 
(statins), calcium-based phosphate binders and vitamin 
D analogues.
 Patients receiving haemodiafiltration had a longer di-
alysis vintage, but median urine output was <50 ml/day 
in all groups. Dialysis session times did not differ, and 
there were no differences in dialysate composition be-
tween haemodialysis and haemodiafiltration groups (so-
dium 137.7 ± 0.9 vs. 137.5 ± 1.2 mmol/l, calcium 1.28 ± 
0.17 vs. 1.24 ± 0.16 mmol/l, potassium 2.0 ± 0.5 vs. 1.78 
mmol/l, respectively). The median convective volume for 
the haemodiafiltration group was 18.6 l/session (16.8–
22.2). There were no differences in vascular access (hae-
modialysis: 66.7% arteriovenous fistula, 26.1% central ve-
nous catheters; haemodialysis to haemodiafiltration: 59% 
arteriovenous fistula, 39.7% central venous catheters; 
haemodiafiltration 71.8% arteriovenous fistula, 23.3% 
central venous catheters, the remainder dialysing with ar-
teriovenous grafts).
 There were no differences in the initial or repeat pe-
ripheral brachial pre-dialysis blood pressure or aortic 
PWV measurements between the 3 groups ( table 3 ).
Table 2. Baseline biochemical results of and bone mineral medications from the patients on high-flux haemodi-
alysis (HD) and online post-dilution haemodiafiltration (HDF), and those who converted from HD to HDF
HD HD to HDF HDF
Albumin, g/l 40.2 ± 4.2 39.9 ± 3.9 39.4 ± 3.8
Calcium, mmol/l 2.31 ± 0.16 2.23 ± 0.18 2.27 ± 0.17
Phosphate, mmol/l 1.49 ± 0.52 1.42 ± 0.46 1.50 ± 0.47
PTH, pmol/l 23.1 (13.2 – 47.4) 27.1 (13.8 – 57.8) 27.5 (15 – 53.4)
ALP, IU/l 96 (77 – 136) 96 (72 – 134) 103 (71 – 137)
Cholesterol, mmol/l 3.87 ± 0.98 3.99 ± 1.11 4.02 ± 1.13
HDL, mmol/l 1.24 ± 0.43 1.31 ± 0.49 1.26 ± 0.5
LDL, mmol/l 1.96 ± 0.83 1.97 ± 0.89 2.1 ± 0.93
Triglycerides, mmol/l 1.2 (0.8 – 1.9) 1.3 (0.9 – 2.3) 1.3 (0.9 – 1.8)
Statins, % 55.1 61.5 58.5
Alfacalcidol, μg/week 2 (0.75 – 4.63) 1.75 (0.75 – 6.0) 2 (0.75 – 4.5)
Calcium carbonate, % 50.7 53.8 53.5
Sevelamer, % 10.1 9.0 21.8
Lanthanum, % 11.6 12.8 18.2
Cinacalcet, % 8.7 2.6 9.9
Results are means ± SD or medians (interquartile ranges). PTH = Parathyroid hormone; ALP = alkaline phos-
phatase. Statistical testing by χ2 or t test with post hoc correction versus HD did not show any differences.
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 However, whereas the measured PWV increased 
over the 6-month period for both the haemodialysis and 
the haemodialysis changing to haemodiafiltration 
groups, there was no overall increase for the haemo-
diafiltration cohort ( fig. 1 ). There were no differences in 
the brachial and aortic augmentation indices either be-
tween or within the groups, although there was a trend 
to an increase after 6 months of haemodialysis; the me-
dian percentage increased from 9.1 and 5.3% for the 
brachial and aortic arteries, respectively, whereas the 
median percentage changes in augmentation indices af-
ter 6 months of haemodiafiltration were –1.4 and –1.7%, 
respectively. There were no differences between the 
groups for the DRA, but whereas the mean DRA in-
creased in the haemodiafiltration cohorts, it fell in the 
haemodialysis group ( fig. 2 ).
 Table 3.  Blood pressure and aortic PWV measurements from the patients on high-flux haemodialysis (HD) and 
online post-dilution haemodiafiltration (HDF), and those who converted from HD to HDF taken during 2 audits 
(1 and 2) 6 months apart
HD HD to HDF HDF
Heart rate 1, bpm 72.8 ± 13.3 73.1 ± 13.4 73.4 ± 14.2
Heart rate 2, bpm 78.4 ± 16.0 76.6 ± 14.3 74.5 ± 14.0
SBP-1, mm Hg 142.6 ± 24.9 153.0 ± 26.2 148.7 ± 31.2
SBP-2, mm Hg 146.1 ± 27.1 154.0 ± 24.6 148.4 ± 30.0
DBP-1, mm Hg 76.5 ± 12.8 85.8 ± 15.9 78.9 ± 15.8
DBP-2, mm Hg 80.0 ± 16.1 83.6 ± 17.1 79.6 ± 17.0
PP-1, mm Hg 66.1 ± 18.5 67.3 ± 17.1 69.8 ± 21.9
PP-2, mm Hg 66.1 ± 18.5 70.5 ± 17.3 68.9 ± 19.8
SBP Ao-1, mm Hg 143.6 ± 30 154.9 ± 30.9 149.9 ± 35.6
SBP Ao-2, mm Hg 146.1 ± 30.9 155.4 ± 28.2 149.8 ± 34.1
BrAXi-1 1.9 (–32.5 to 28.4) 5.3 (–16.9 to 28.4) 3.6 (–32.2 to 31.4)
BrAXi-2 0.1 (–27 to 28.4) 3.4 (–16.3 to 23.3) 4.0 (–26.2 to 23.3)
AoAXi-1 36.3 ± 16.1 38.5 ± 14.4 39.5 ± 17.3
AoAXi-2 37.8 ± 16.1 41.2 ± 14.4 40.0 ± 15.9
 SBP = Systolic blood pressure; DBP = diastolic blood pressure; PP = pulse pressure; Ao = aorta. Augmenta-
tion indices (AXi) of the brachial artery (BrAXi) and aorta (AoAXi) were all adjusted for heart rate. Results are 
means ± SD or medians (interquartile ranges). No significant differences between the groups were found.
 Table 4.  Results of transthoracic echocardiography (ECHO) and isotope heart stress test from the patients on 
high-flux haemodialysis (HD) and online post-dilution haemodiafiltration (HDF), and those who converted 
from HD to HDF prior to the audit
HD HD to HDF HDF
ECHO, n (%) 37 (53.6) 59 (75.6) 91 (64.1)
Ejection fraction, % 60 (55 – 60) 60 (45 – 60) 60 (50 – 60)
LVEDD, cm 4.79 ± 0.59 4.61 ± 0.74 4.66 ± 0.72
LV mass, g 211 (164 – 257) 206 (153 – 270) 213 (164 – 279)
LVMI, g/m2 116 (97 – 134) 113 (87 – 141) 126 (100 – 148)
Exercise test, n (%) 22 (31.9) 50 (64.1) 52 (36.6)
Positive test, % 59.1 54 34.6
 Total number (%) of patients tested in each group. LVEDD = Left ventricular end-diastolic diameter; LV = 
left ventricle; LVMI = left ventricular mass index. Positive heart stress is defined as reversible changes in cardiac 
perfusion between stress and rest images. Results are means ±SD or medians (interquartile ranges). No significant 
differences between the groups were found.
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 To determine whether there was an effect of dialysis 
vintage, patients were divided into tertiles, and there was 
no difference in initial PWV (lowest to highest tertiles: 
9.02 ± 2.1 vs. 9.56 ± 3.2 vs. 9.93 ± 3.2 m/s, respectively) or 
PWV on follow-up (9.46 ± 2.7 vs. 9.88 ± 3.5 vs. 9.87 ± 3.5 
m/s, respectively). We then divided the haemodiafiltra-
tion group into tertiles by vintage, and again there was no 
difference between the tertiles (online suppl. table 2).
 We then analysed the change in PWV according to the 
initial PWV by diving the whole cohort into tertiles (on-
line suppl. table  3). Whereas PWV increased by 0.55 
(0.28–2.89) m/s for those starting in the lowest PWV ter-
tile, it decreased in the highest tertile group [–1.48 (–3.49 
to 0.32) m/s, p < 0.001]. Patients were then divided into 
tertiles for the different treatment modalities (online
suppl. table  3). Although there was a difference in the 
change in PWV between the lowest and highest starting 
tertile for the haemodialysis group [0.55 (0.28–2.89) vs. 
–0.37 (–2.93 to 2.17), p < 0.05], this difference was much 
greater for the haemodiafiltration cohort [0.61 (0.16–
2.08) vs. –1.88 (–3.47 to –0.28), p < 0.001].
 Transthoracic echocardiograms were available for 187 
patients ( table 4 ). There were no significant differences in 
left ventricular hypertrophy or left ventricular ejection 
fraction. A minority of patients had undergone isotope 
heart stress testing, but a similar percentage of patients 
had demonstrable ischaemic heart disease.
 Discussion 
 The majority of studies measuring PWV in dialysis pa-
tients have measured carotid-femoral or brachial-ankle 
PWV, so measuring a composite of aortic and conduit 
arteries  [4] , and thus overestimating aortic PWV  [10] . 
More recently, aortic PWV has been reported to be an 
important independent risk factor for cardiovascular 
mortality in the general population  [17] . Our 3 groups 
were relatively well matched for systolic hypertension, 
age, sex, body mass index and co-morbid conditions, in-
cluding type 2 diabetes mellitus, which are recognised to 
affect PWV  [3, 4] . Self-reported smoking habits were 
greater in the haemodialysis group, but there was no dif-
ference between the groups comparing non-smokers 
with ex- and current smokers.
 Compared to previous studies measuring a composite 
of aortic and conduit PWV, our aortic pulse wave mea-
surements were lower  [18, 19] . The device used in our 
study has been validated against direct invasive measure-
ments  [9, 11] , and, by measuring the time required for the 
pulse wave to travel from the aortic root down to the aor-
tic bifurcation and return coupled with the distance trav-
elled, does not overestimate PWV  [10, 18] . However, the 
device requires a minimum of three sinus beats and as 
such could not be used to measure PWV in patients with 
atrial fibrillation.
 Our results showed an increase in aortic PWV in pa-
tients who remained on haemodialysis or were only re-
cently transferred to haemodiafiltration, whereas there was 
no overall increase for those established on haemodiafiltra-
tion, and are supported by two earlier smaller single-centre 
studies: one reporting that patients dialysing with haemo-
1st audit
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 Fig. 1. Aortic PWV measured at two audits (taken 6 months apart) 
in 3 cohorts: those remaining on haemodialysis (HD), those con-
verted from HD to haemodiafiltration (HDF) and those treated by 
HDF. Data are means ± SEM.  * *  p < 0.01 vs. initial measurement. 
 Fig. 2. DRA derived from PWV measurements at two audits (tak-
en 6 months apart) in 3 cohorts: those remaining on haemodialysis 
(HD), those converted from HD to haemodiafiltration (HDF) and 
those treated with HDF. Data are adjusted for heart rate and ex-
pressed as means ± SEM.  *  p < 0.05 vs. initial measurement. 
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diafiltration had lower PWV measurements than those 
treated by conventional haemodialysis  [20] and another 
noting increased PWV in haemodialysis patients, but with 
no increase with haemodiafiltration  [21] . Although anoth-
er study observed no differences in carotid-femoral PWV 
between haemodialysis and haemodiafiltration groups 
 [22] , this negative study of just over 100 patients employed 
multiple observers making a limited number of measure-
ments in a younger dialysis population with fewer diabetics 
with no correction for heart rate. PWV is affected by pe-
ripheral blood pressure, vascular resistance and cardiac 
output, in keeping with these earlier studies.
 Our haemodiafiltration patients had a longer dialysis 
vintage, and as such this may have affected PWV. Analys-
ing the whole cohort, and then the effects of vintage for 
each of the three treatment modalities, we could not dem-
onstrate a major effect of vintage on PWV. However, we 
did not have data on the time patients spent progressing 
through CKD stages 4 and 5 prior to the initiation of di-
alysis, and this may be an important factor as PWV has 
been reported to be increased in patients with CKD.
 To ensure that changes in PWV are not simply deter-
mined by the initial PWV, with there being a maximum 
PWV above which further increases are limited due to a 
plateau effect, we analysed patients by their first PWV 
measurement. We did find that whereas PWV increased 
in those patients in the lowest starting tertile, there was a 
reduction for those in the highest tertile, and this differ-
ence was statistically greater for the haemodiafiltration 
cohort compared to the haemodialysis cohort.
 Changes in vascular stiffness could reflect changes in 
vascular calcification, and although haemodiafiltration 
has been reported to improve serum phosphate control, 
this effect is generally modest  [7] . Although there was a 
trend for the haemodiafiltration patients to be prescribed 
non-calcium-containing phosphate binders, this was not 
significant, and all groups were equally prescribed calci-
um-based phosphate binders. Whether haemodiafiltra-
tion has any beneficial effect on the regulators controlling 
soft tissue calcification remains to be determined. There 
could be subtle changes in the flux of sodium and calcium 
during haemodiafiltration compared to haemodialysis 
treatments due to higher volume convective therapy cou-
pled with a cooling effect compared to the diffusional ex-
change with haemodialysis  [23] , which could potentially 
then affect vascular stiffness by altering medial calcium 
and sodium content.
 To determine whether haemodiafiltration had any ef-
fect on arterial tone, we measured the augmentation in-
dex of the brachial artery and aorta. The lower the aug-
mentation index then the greater the degree of arterial 
dilatation. As the augmentation index is affected by heart 
rate, all measurements were analysed after being stan-
dardised for heart rate. We did not find any significant 
changes in augmentation indices, although there was a 
trend to increase with haemodialysis, with no change for 
haemodiafiltration. This could potentially suggest im-
provement in endothelial function, and there are reports 
of reduced endothelial inflammation  [24] and increased 
brachial flow-mediated dilatation and carotid artery dis-
tensibility with haemodiafiltration compared to haemo-
dialysis  [25] .
 An increase in DRA, a derived index reflecting dia-
stolic filling, is associated with greater filling of the left 
coronary artery during diastole. There was a trend for the 
DRA to increase after 6 months of haemodiafiltration 
with no change in the haemodialysis cohort. Increasing 
DRA improves cardiac perfusion, and as such this may 
potentially reduce the risk of myocardial stunning with 
haemodiafiltration  [8, 26] . Haemodiafiltration addition-
ally leads to greater thermal losses during treatment, and 
this may also help reduce the risk of intradialytic hypo-
tension.
 Our observational study suggested that although there 
were no differences in peripheral or central blood pres-
sure after 6 months of haemodiafiltration, there were dif-
ferences in PWV compared to haemodialysis. The great-
est effect was observed in those patients starting with 
higher initial PWV. These changes were associated with 
improvement in cardiac diastolic perfusion and reduc-
tion in aortic and brachial augmentation indices. Taken 
together this would suggest a benefit for haemodiafiltra-
tion. However, our results have to be viewed in the con-
text that we only measured changes over a 6-month pe-
riod and that haemodiafiltration patients had a longer di-
alysis vintage, with fewer self-reported current smokers, 
and that PWV measurements were not possible in all pa-
tients. As such, further studies are required to confirm 
these preliminary findings and determine the underlying 
aetiology.
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